Document is current
Any future updates will be listed below
-
Authors
Bellando-Randone, S.
Wilhalme, H.
Bruni, C.
Czirjak, L.
Distler, O.
Allanore, Y.
Cuomo, G.
Denton, C.
Del Galdo, F.
Gheorghiu, A. M.
Riccieri, V.
Walker, U.
Truchetet, M. E.
Vonk, M. C.
Foeldvari, I.
Matucci-Cerinic, M.
Furst, D. E.
,
Cerinic, Marco Matucci
Walker, Ulrich
Iannone, Florenzo
Guiducci, Serena
Becvar, Radim
Valentini, Gabriele
Siegert, Elise
Montecucco, C.
Carreira, Patricia E.
Chizzolini, Carlo
Kucharz, Eugene J.
Doria, Andrea
Bancel, Pr Dominique Farge
Hesselstrand, Roger
Balbir-Gurman, Alexandra
Pellerito, Raffaele
Caimmi, Cristian
Denton, Christopher
Damjanov, Nemanja
Henes, Jörg
Ortiz-Santamaria Granollers, Vera
Heitmann, Stefan
Salvador, Maria João
Stamenkovic, Bojana
Selmi, Carlo Francesco
Herrick, Ariane
MüllerLadner, Ulf
Engelhart, Merete
Riccieri, Valeria
Ionescu, Ruxandra Maria
Gheorghiu, Ana Maria
Sunderkötter, Cord
Distler, Jörg
Ingegnoli, Francesca
Mouthon, Luc
Smith, Vanessa
Cantatore, Francesco Paolo
Ullman, Susanne
Pozzi, Maria Rosa
Wiland, Piotr
Vanthuyne, Marie
Krummel-Lorenz, Brigitte
Saar, Petra
Herrmann, Kristine
De Langhe, Ellen
Anic, Branimir
Baresic, Marko
Mayer, Miroslav
Yavuz, Sule
de Souza Müller, Carolina
Zenone, Thierry
Mathieu, Alessandro
Vacca, Alessandra
Solanki, Kamal
Rosato, Edoardo
Yargucu, Fahrettin Oksel Figen
Tanaseanu, Cristina-Mihaela
Foti, Rosario
Furst, Daniel E.
Adler, Peter Villiger Sabine
de la Peña Lefebvre, Paloma García
Martín, Jorge Juan González
Litinsky, Ira
Del Galdo, Francesco
Seskute, Goda
Saketkoo, Lesley Ann
Kerzberg, Eduardo
Castellví, Ivan
Spertini, François
Hsu, Vivien M.
Martin, Thierry
Schmeiser, Tim
Majewski, Dominik
Bernardino, Vera
Puttini, Piercarlo Sarzi
- License Information
-
More Information
Article History
Received: 2 December 2023
Accepted: 7 January 2025
First Online: 27 March 2025
Declarations
:
: All contributing EUSTAR centres have obtained approval from their respective local ethics committee for including patients’ data in the EUSTAR database and written informed consent was obtained in those centres, where required by the ethics committee.
: Not applicable.
: Bruni C: speaker for Eli-Lilly, consulting for Boehringer Ingelheim. Research grants from Foundation for Research in Rheumatology (FOREUM), Gruppo Italiano Lotta alla Sclerodermia (GILS), European Scleroderma Trials and Research Group (EUSTAR), Foundation for research in Rheumatology (FOREUM), Scleroderma Clinical Trials Consortium (SCTC) and Scleroderma Research Foundation (SRF). Educational grants from AbbVie outside the submitted work. Distler O has/had consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, Horizon, Janssen, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Prometheus, Redxpharma, Roivant and Topadur. Co-founder of Citus AG. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143)outside the submitted work.
: Distler O has/had consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, Horizon, Janssen, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Prometheus, Redxpharma, Roivant and Topadur. Co-founder of Citus AG. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143) Outside the submitted work.
